Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

Aurisco Pharmaceutical Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	1,704	1,697	1,476	1,263	1,008	803.36
Revenue Growth	8.73%	15.02%	16.89%	25.24%	25.48%	11.36%
Gross Profit Gross Profit Growth	960.47	1,000	844.36	698.32	512.57	394.72
Operating Income Operating Income Growth	484.02	532.56	386.4	278.83	208.21	182.76
Net Income Net Income Growth	373.06	449.21	354.79	289.42	210.96	168.71
Earnings Per Share EPS Growth	0.91	1.10	0.89	0.71	0.52	0.42
EPS Growth	-10.00%	23.60%	25.35%	36.54%	23.81%	0%

Revenue by Segment

Chart

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Sales of active pharmaceutical ingredients and Intermediates Sales of active pharmaceutical ingredients and Intermediates Growth	1,468	1,141
Sale of Drug Product Sale of Drug Product Growth	184.4	220.02
Trading of active pharmaceutical ingredients and intermediates Trading of active pharmaceutical ingredients and intermediates Growth	36	111.39
Others Others Growth	8.73	3.67
Total Total Growth	1,697	1,476

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	720.92	953.9	1,069	545.84	391.74	444.61
Total Debt Total Debt Growth	970.02	958.97	947.85	116.88	52.69	17.97
Net Cash (Debt) Net Cash Growth	-249.1	-5.07	121.42	428.95	339.05	426.64
Net Cash Growth	-	-	-71.69%	26.52%	-20.53%	-24.37%
Net Cash Per Share Net Cash Per Share Growth	-0.61	-0.01	0.30	1.05	0.84	1.06

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	413.89	421.5	332.41	385.61	166.41	201.57
Capital Expenditures CapEx Growth	-388.16	-350.07	-540.28	-305.48	-216.23	-250.61
Free Cash Flow Free Cash Flow Growth	25.73	71.42	-207.87	80.13	-49.82	-49.04
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	56.37%	58.92%	57.22%	55.31%	50.85%	49.13%
Operating Margin	28.41%	31.37%	26.18%	22.09%	20.65%	22.75%
Pretax Margin	25.55%	30.53%	27.61%	26.07%	23.88%	23.90%
Profit Margin	21.89%	26.46%	24.04%	22.92%	20.93%	21.00%
FCF Margin	1.51%	4.21%	-14.09%	6.35%	-4.94%	-6.11%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 11, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	0.340	0.340	0.290	0.220	0.160	0.130
Dividend Per Share Growth	17.24%	17.24%	31.82%	37.50%	23.08%	8.33%
Dividend Yield	1.71%	1.38%	1.42%	0.89%	0.68%	0.62%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 11, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	21.07	22.65	24.18	36.24	47.54	52.34
Forward PE	-	20.20	18.69	30.47	39.82	44.04
P/FCF Ratio	300.97	142.46	-	130.89	-	-
PS Ratio	4.55	5.99	5.81	8.31	9.95	10.99

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 11, 2026

Data Sources Report a data error